NASDAQ$LYEL
Lyell Immunopharma Inc · Q3 2022 earnings
Q3 2022 earnings · · Investor relations
Briefing
Lyell Immunopharma reported financial results for the third quarter of 2022.
Lyell Immunopharma reported a net loss of $70.3 million for the third quarter ended September 30, 2022. Cash, cash equivalents and marketable securities as of September 30, 2022 were $750.7 million, which extends funding into 2026.
- IND application for LYL845 cleared, advancing second wholly owned product candidate into clinical development.
- Cash, cash equivalents and marketable securities of $750.7 million as of September 30, 2022, extends funding into 2026.
- Advanced two product candidates into clinical development and added LYL119 to pipeline.
- Initial clinical data from LYL797 and LYL845 expected in 2024.
Headline financials
Revenue & EPS history
Lyell Immunopharma · Revenue · Quarterly
$3K
Forward guidance
Lyell believes that its cash, cash equivalents and marketable securities balances will be sufficient to meet working capital and capital expenditure needs into 2026.
Tailwinds
- Cash runway into 2026
- Advancement of multiple product candidates through key clinical milestones
- Initial clinical data from both wholly owned product candidates, LYL797 and LYL845, expected
- Expense timing
- Diligent expense management
Headwinds
- Effects of the COVID-19 pandemic
- Geopolitical instability
- Macroeconomic conditions
- Lack of experience as a company in enrolling, conducting or completing clinical trials
- Potential for results from clinical trials to differ from preclinical, early clinical, preliminary or expected results
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q3 2022
+1.5%
Avg return
Earnings day
-4.0%
Avg return
5 days after
+1.1%
Avg return
30 days after
73%
16 / 22 earnings
Positive
+20.3%
Q4 2024
Best reaction
-18.3%
Q3 2022
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +1.1% | -7.0% | -42.1% | |
| Q4 2025 | +2.5% | -19.0% | -9.6% | |
| Q3 2025 | -1.3% | +1.7% | +95.5% | |
| Q1 2025 | +4.6% | +2.0% | +21.1% | |
| Q4 2024 | +20.3% | +15.5% | -10.3% | |
| Q3 2024 | -17.6% | -21.3% | -38.9% | |
| Q2 2024 | +1.4% | -8.1% | -20.9% | |
| Q1 2024 | +7.6% | +4.2% | +13.6% | |
| Q4 2023 | +2.5% | -8.6% | -21.8% | |
| Q3 2023 | +6.8% | -24.8% | -11.8% | |
| Q2 2023 | +1.5% | -1.9% | -16.8% | |
| Q1 2023 | +6.9% | +6.5% | +50.9% | |
| Q4 2022 | +9.6% | +1.4% | -1.8% | |
| Q3 2022 | -18.3% | -17.0% | -28.8% | |
| Q2 2022 | +16.3% | +20.2% | +10.1% | |
| Q1 2021 | -12.4% | -22.8% | +1.5% | |
| Q1 2022 | -12.4% | -22.8% | +1.5% | |
| Q4 2019 | +6.1% | +6.1% | +1.6% | |
| Q4 2021 | +6.1% | +6.1% | +1.6% | |
| Q3 2021 | -4.1% | -3.6% | -18.8% | |
| Q4 2020 | +2.8% | +2.2% | +24.6% | |
| Q2 2021 | +2.8% | +2.2% | +24.6% | |
| Q3 2020 | — | — | — | |
| Q2 2020 | — | — | — | |
| Q1 2020 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro